BeyondSpring, Inc. · NASDAQ:BYSI

BeyondSpring — Investor Presentation (September 2023)

40 slides from BeyondSpring's investor presentation, September 2023

  1. Slide 1: September 2023 | NASDAQ: BYSI

    September 2023 | NASDAQ: BYSI

  2. Slide 2: Disclaimer

    Disclaimer This presentation has been prepared for informational purposes only. No money or other consideration is being solicited, and if sent in response, will not be accepted. This presentation shall not constitute an offer to sell, or the solicitation of an offer to buy, any securities, nor shal

  3. Slide 3: Investment Highlights

    Investment Highlights Plinabulin: Safety Lead Asset Plinabulin: >700 cancer patients treated with good & Efficacy tolerability; Positive Phase 3 data in 2 indications Plinabulin Plinabulin: Dual Benefit in anti-cancer and prevention of CIN; Potential Potential in re-sensitizing in PD-1/PD-L1 progres

  4. Slide 4: Pipeline

    Pipeline Indication/Target Program Preclinical Phase 1 Phase 2 Phase 3 Registration Trial Name / Collaborator NSCLC Plinabulin + Docetaxel DUBLIN-3 Late stage (2nd/3rd line) Plinabulin + PROTECTIVE-1 CIN Prevention Pegfilgrastim & PROTECTIVE-2 SCLC Plinabulin + PD-1 + (2nd/3rd line) CTLA-4 Investiga

  5. Slide 5: Plinabulin: Induce Innate and Adaptive Immunity

    Plinabulin: Induce Innate and Adaptive Immunity By depolymerizing microtubules, plinabulin releases, or activates, immune-defense protein GEF-H1. This leads to dendritic cell maturation (the most potent APC). In WT DC cells, plinabulin can induce DC maturation, but not in GEF-H1 deleted DC cells2 Pl

  6. Slide 6: Plinabulin Franchise

    Plinabulin Franchise Clinical Confirmation Expand Transform Promising early clinical efficacy data Positive topline Phase 3 OS data Confirmed in 6 clinical studies & NDA Review in China CIN NSCLC Multiple Cancers (I/O Combo) 6

  7. Slide 7: SEED Therapeutics: Target Protein Degradation (TPD) Company

    SEED Therapeutics: Target Protein Degradation (TPD) Company 7

  8. Slide 8: SEED Therapeutics

    SEED Therapeutics Founders: • Avram Hershko, MD PhD (Nobel Prize Winner, Technion), a world expert in ubiquitin-mediated TPD research; • Ning Zheng, PhD (HHMI, Pharmacology Dept, University of Washington), a pioneer in structural biology of ubiquitin E3 ligases; • Michele Pagano, MD (HHMI, Chairman,

  9. Slide 9: TPD Targets 80% of Disease-Causing Proteins That Are Currently Undruggable

    Targeted Protein Degradation (TPD) Targets 80% of Disease-Causing Proteins That are Currently Undruggable Druggable Proteins TPD for Undruggable Proteins https://doi.org/10.1124/mol.117.111062 9

  10. Slide 10: Nature Derived TPD Molecular Glue Approved To Degrade Cancer-causing Proteins

    Nature Derived TPD Molecular Glue Approved To Degrade Cancer- causing Proteins Normal cell protein regulation via proteasomal degradation • Natural method for selective protein degradation • Nature derived IMIDs are approved molecular glues that hijack E3 ligases to degrade cancer causing proteins S

  11. Slide 11: Strong Scientific Foundation With Proven Execution Capability

    Strong Scientific Foundation With Proven Execution Capability to Timely Deliver Drug Pipeline for Multiple Unmet Medical Needs World-Leading Scientific Expertise → Translate to Drug Pipeline Avram Hershko Ning Zheng, Michele James Tonra, Lan Huang, PhD MD, PhD PhD Pagano, MD PhD Pioneer in the Pione

  12. Slide 12: Exceeding Seed Financing Expectations

    Exceeding Seed Financing Expectations SEED Internal Program Milestones Translation of SEED Platforms into Drug Development of SEED’s unique TPD platforms and filed Infrastructure and Organization Pipeline of 7 disclosed programs in patents Building various disease areas • Multi-dimensional platforms

  13. Slide 13: How SEED Differentiates Itself in Surmounting Challenges

    How SEED Differentiates Itself in Surmounting Challenges Unique How to identify the right E3 for protein of interest (POI)? Challenges Target-Centric Identify the right E3 for POI to increase the success rate in drug Differentiation discovery: Platforms using Quasi-degron, LumID, and Basal Affinity

  14. Slide 14: SEED's Multi-dimensional, Proprietary Platform for E3 Selection

    SEED’s Multi-dimensional, Proprietary Platform for E3 Selection Knowledge-based Direct Binding Validation LumID: Identify the right E3 in the Quasi Degron Approach “living cell” near protein of interest B B E3 B Target Neo Target Neo Target 1 Quasi Degron B Weakened Binding I L I L E3 C A A E3 A E3

  15. Slide 15: 7 Drug R&D Pipeline in Multiple Disease Areas

    7 Drug R&D Pipeline in Multiple Disease Areas Target Protein Target Molecular Indication / Target E3 Ligase ID Lead ID IND Candidate IND Filing Initiative* Selection Glue HTS Target Alpha NeuroD Tau Project X 1st IND 2024 KRAS-G12D Cancer Target Beta FEN1 Antiviral HBx * 6 of 7 Targets Unpartnered 1

  16. Slide 16: Project X: Lead ST-00973 Expected to Enter IND in 2024

    Project X: Lead ST-00973 Expected to Enter IND in 2024 POC: Degradation of Target protein Superb In Vivo Efficacy: Good In Vivo Safety: in Cell Complete Tumor Regression No Weight Loss 6h 24h 1000 35 Tumor Volume(mm3) 800 Body Weight (g) 30 600 Target Protein 25 400 200 20 Vinculin 0 15 0 3 6 9 12 0

  17. Slide 17: SEED (TPD 2.0) - Differentiated among High-value TPD Companies

    SEED (TPD 2.0) - Differentiated among High-value TPD Companies Molecular Glue/Monovalent Pharma Companies Licensing Deals in E3:Target Protein TPD Assets Basal Interaction Discovery: Basal LumID • Deal Size Affinity • Upfront: $40 - $415 M Sold to Bayer for Quasi-Interface 1.5 B upfront • Milestone:

  18. Slide 18: Summary: First to Market and Best in Class

    Summary: First to Market and Best in Class 1. Target-centric SEED Breakthrough TPD Platforms Employ Multi-dimensional Proprietary Platforms for E3 Selection • 80% of disease-causing proteins are undruggable, presenting a tremendous medical opportunity for SEED’s new drug development platform; • With

  19. Slide 19: Plinabulin: Chemotherapy-Induced Neutropenia (CIN) Prevention Indication

    Plinabulin: Chemotherapy-Induced Neutropenia (CIN) Prevention Indication 19

  20. Slide 20: CIN: Unmet Medical Need in Low White Blood Cell Count

    CIN: Unmet Medical Need in Low White Blood Cell Count (depth of Neutropenia) in Week 1 After Chemotherapy Despite widespread G-CSF use, CIN is #1 reason for FN, ER visits, hospitalization, sepsis, mortality, and chemotherapy dose reduction and disruption1 Short-term Long-term G-CSF can reduce the du

  21. Slide 21: Six Clinical Studies Confirm Plinabulin's Neutropenia Prevention Benefit

    Six Clinical Studies Confirm Plinabulin’s Neutropenia Prevention Benefit Plinabulin enables more use of chemotherapy ANC-based Benefit Clinical Benefit Study 101 (Phase 2) Grade 3/4 Neutropenia (C1D8): Sepsis: 0% Plinabulin vs. 3.6% Placebo - Docetaxel, NSCLC Plinabulin (n=90, 10% G-CSF): 7% vs. Sev

  22. Slide 22: PROTECTIVE-2 (106 Study, Phase 2): Rationale for the Combination

    PROTECTIVE-2 (106 Study, Phase 2): Rationale for the Combination ANC in Cycle 1 After TAC for Breast Cancer - Pegfilgrastim Unmet need in ANC protection in Week 1 - Plinabulin fills the Gap Pegfilgrastim vs Plinabulin Plinabulin + Pegfilgrastim vs Pegfilgrastim 7 Pegfilgrastim (6.0 mg) (n=22) Pegfil

  23. Slide 23: Met Primary Endpoint in PROTECTIVE-2 (106 Study) Phase 2

    Met Primary Endpoint in PROTECTIVE-2 (106 Study) Phase 3 Design: Double blind, global study (19 centers); 4 cycles Plinabulin 40 mg + Pegfilgrastim 6 mg N=111 Breast Cancer, R TAC Therapy 1:1 Placebo + Pegfilgrastim 6 mg N=110 Results: Proportion of Patients with NO Grade 4 Neutropenia (or DSN= 0 Da

  24. Slide 24: Superior Improvement Seen with the Combination Compared to Pegfilgrastim Alone

    106 Phase 3: Superior Improvement Seen with the Combination in Clinically Meaningful Endpoints Compared to Pegfilgrastim Alone Reduction of Incidence and Reduction of Profound Severity of FN and Neutropenia (PN) Related Hospitalization Benefits Plinabulin improves depth of neutropenia Clinical Endpo

  25. Slide 25: Potential for Use Across the Spectrum of Solid Tumors

    Potential for Use Across the Spectrum of Solid Tumors G-CSF Administrations: Across Solid Tumor Gynecologic Rectal al Cancer, Cancer Other 5% Plinabulin Differentiated Benefit for Ovarian Cancer 5% CIN Prevention compared with G-CSF 5% • Improve depth of neutropenia; Prostate Cancer 6% Female • Firs

  26. Slide 26: 2nd/3rd Line NSCLC Indication

    2nd/3rd Line NSCLC Indication 26

  27. Slide 27: 2L/3L NSCLC, no Driver Mutation: Docetaxel as Standard of Care

    2L/3L NSCLC, no Driver Mutation: Docetaxel as Standard of Care (SOC) With PD-1/PD-L1 moving to 1L, Docetaxel remains SOC for 2L/3L NSCLC Pemetrexed and PD-1/PD-L1 Moved To First Line Ramuciramab + Docetaxel vs. Treatment Pemetrexed vs Docetaxel2 Nivolumab (PD-1 Ab) vs. Docetaxel3 Docetaxel1 Limited

  28. Slide 28: DUBLIN-3 (Study 103) Trial Design

    DUBLIN-3 (Study 103) Trial Design Docetaxel + Plinabulin vs. Docetaxel + Placebo in Patients with EGFR Wild-Type NSCLC End Points: Primary Endpoint: OS Secondary Endpoints: Study Plan: • ORR, PFS • Global, randomized, single-blinded (patients only) • Percent of patients without severe neutropenia on

  29. Slide 29: Met Primary Endpoint of OS; Significantly Improve 2-, 3-year OS Rate

    Met Primary Endpoint of OS; Significantly Improve 2-, 3-year OS Rate 100 Docetaxel Docetaxel+ plinabulin Docetaxel Docetaxel + placebo Censored + Plinabulin (DP) + Placebo (D) 80 Survival Probability (%) DP (n=278) D (n=281) Events, n(%) 214 (77.0) 230 (81.9) 60 Median overall survival 10.5 9.4 43.4

  30. Slide 30: Significant Reduction in Grade 4 Neutropenia

    Significant Reduction in Grade 4 Neutropenia Cycle 1 Day 8 and All Cycles Day 8 Grade 4 neutropenia, Cycle 1 Day 8 Grade 4 neutropenia, All Cycles Day 8 50% 50% P<0.0001 P<0.0001 40% 40% Percentage of Patients Percentage of Patients 33.58% 30% 27.80% 30% 20% 20% 10% 10% 5.26% 5.13% 0% 0% Docetaxel +

  31. Slide 31: Significant Improvement in Quality of Life Benefit

    Anti- Significant Improvement in Quality of Life Benefit Cancer - Q-TWiST (Quality-Adjusted Time Without Symptoms of Disease and Toxicity) Plinabulin + Docetaxel Twist alone Clinically Meaningful Improvement of >18% in Q-TWiST. 31

  32. Slide 32: Potential Benefit of Plinabulin + Docetaxel in 2L/3L NSCLC

    Potential Benefit of Plinabulin + Docetaxel in 2L/3L NSCLC, No Driver Mutation With PD-1/PD-L1 moving to 1st line NSCLC, plinabulin + docetaxel could be the potential choice. Benefits compared to SOC Docetaxel: Efficacy: • Significant survival benefit in ITT (OS HR=0.82), with more pronounced surviv

  33. Slide 33: Immuno-Oncology Combinations

    Immuno-Oncology Combinations 33

  34. Slide 34: Mechanism with Broad Applications

    Mechanism with Broad Applications Plinabulin Induces Dendritic Cell Maturation (the most potent APC), a Key Step in Initiating Anti-Cancer Durable Response ❷ Plinabulin ❸ Checkpoint Inhibitors Hit the Gas Release The Brakes Stimulates maturation of dendritic Optimize T cell response cells to increas

  35. Slide 35: Clinical POC in Triple Plinabulin IO Combination Regimen

    Clinical POC in Triple Plinabulin IO Combination Regimen Indication / Program Preclinical Phase 1 Phase 2 Phase 3 Collaborator Target 7 cancers Plinabulin + PD-1/PD-L1 + (PD-1/PD-L1 Radiation progressed) NSCLC (2L/3L, PD-1/PD-L1 Plinabulin + PD-1 + Docetaxel progressed) MD Anderson Phase 1 study cli

  36. Slide 36: Plinabulin as Potential Add-on Therapy to Current I/O Regimens

    Plinabulin as Potential Add-on Therapy to Current I/O Regimens to Address Severe Unmet Medical Needs PD-1/PD-L1 Inhibitors Potential to greatly expand the - $30B global annual sales addressable market Current Severe Unmet Medical Needs Plinabulin Clinical Development Re-sensitize: Plinabulin + PD-1/

  37. Slide 37: Regulatory Pathway

    np BeyondSpring Regulatory Pathway

  38. Slide 38: Regulatory Pathway

    Regulatory Pathway Near-Term Long-Term CIN: Ongoing discussion with Seek regulatory clarity and NMPA in China and FDA in the additional approvals in countries US; around the world. NSCLC: Ongoing preparation to file for NDA approval in China and the US. 38

  39. Slide 39: Investment Highlights

    Investment Highlights Plinabulin: Safety Lead Asset Plinabulin: >700 cancer patients treated with good & Efficacy tolerability; Positive Phase 3 data in 2 indications Plinabulin Plinabulin: Dual Benefit in anti-cancer and prevention of CIN; Potential Potential in re-sensitizing in PD-1/PD-L1 progres

  40. Slide 40: www.beyondspringpharma.com

    www.beyondspringpharma.com 40

BeyondSpring — Investor Presentation (September 2023) on 6ix